Skip to content
Home page - Centenary Institute Centenary Institute

Primary menu

  • Research
        • Research

          The latest medical research into our most complex health challenges across cancer, cardiovascular disease and inflammation

          Learn more

        • Cancer
        • Inflammation
        • Cardiovascular
        • Programs
        • Laboratories
        • Diseases
        • Expertises
        • Services and instrumentation
  • Support us
        • Support us

          By supporting the Centenary Institute you can help improve human health through excellence in medical research

          Learn more

        • Workplace giving
        • Host or join a fundraiser
        • Gift in your Will
        • Donate in Memory
  • Impact
        • Impact

          Our research develops new diagnostics, treatments and cures for some of the most deadly and debilitating diseases affecting society today

          Learn more

        • Breakthroughs
        • Community and research
        • Real stories
  • Health hub
        • Health hub

          A range of practical information to assist in the possible preventions to disease through evidence-based research on how the body works.

          Learn more

        • Inflammation
        • The Good Gut Anti-Inflammatory Diet
        • Ageing
        • Exercise Snack Program
  • News & events
        • News & Events

          Explore the latest research breakthroughs and ways you can take part in our series of digital and in-person events

        • News
        • Events
        • Media Hub
  • About us
        • About us

          We are world-leading independent medical research institute that drives collaboration to accelerate and translate solutions to our most complex health challenges

          Learn more

        • Governance
        • Corporate information
        • Annual reports
        • Our researchers
        • Careers and studies
        • Contact
  • Donate
    Centenary Institute > News > Sydney researchers test tuberculosis vaccine combination for COVID-19

Sydney researchers test tuberculosis vaccine combination for COVID-19

Date time 2 July, 2020
News Type News type Research News
Sydney researchers are taking an innovative approach to designing potential COVID-19 vaccines - using a tuberculosis vaccine to deliver components of the SARS-CoV-2 virus. Early results from pre-clinical testing in mice are promising.

A University of Sydney news article.

Design uses existing tuberculosis vaccine as key component.

Sydney researchers are taking an innovative approach to designing potential COVID-19 vaccines – using a tuberculosis vaccine to deliver components of the SARS-CoV-2 virus. Early results from pre-clinical testing in mice are promising.

Researchers at the University of Sydney and Centenary Institute are repurposing an existing tuberculosis vaccine to see if it can be used in a new way against COVID-19 to develop a novel vaccine.

The vaccine candidate, which Australian researchers have called BCG:CoVac, combines the vaccine for tuberculosis, Bacille Calmette-Guérin (BCG) with major components of the SARS-CoV-2 virus. The SARS-CoV-2 virus is the pathogen that causes the COVID-19 disease.

The study is part of a collaboration between the University of Sydney and the Centenary Institute to examine the immune response created by new vaccine candidates, including BCG:CoVac.

Lead investigator Professor Jamie Triccas, from the School of Medical Sciences, Faculty of Medicine and Health, and the Charles Perkins Centre (pictured left) said the team was motivated to apply their expertise in studying vaccines to assess the effectiveness of this new formulation.

“We have over two decades of experience in the development and testing of tuberculosis vaccines, which will be applied for the assessment of BCG:CoVac,” said Professor Triccas.

“There have yet to be studies published that combine BCG and components of the SARS-CoV-2 virus as part of a new vaccine design, and we’re excited to test their potential.”

Early results promising

The researchers’ early unpublished results from pre-clinical testing in mice show BCG:CoVac stimulated an immune response aimed to control virus infection in humans.

In mice vaccinated with BCG:CoVac, the vaccine induced high levels of SARS-CoV-2-specific antibodies. The role of these antibodies is to bind the virus and help eliminate it from the body. The vaccine also triggered a strong anti-viral response by T cells (a type of immune cell).

Both these types of immune responses are thought to be important to ensure clearance of the SARS-CoV-2 virus from infected individuals.

Importantly, preliminary data also showed BCG:CoVac did not create high levels of inflammatory responses, which is a common barrier and concern in vaccine design.

“These initial results are very promising. BCG:CoVac is making the type of immune response that we predict is needed to control SARS-CoV-2 infection in humans,” said Professor Triccas.

“We are currently determining how well the antibodies generated after vaccination can ‘block’ the virus from infecting cells and thus provide protection from disease”.

Using the TB vaccine as a vehicle

In BCG:CoVac, the BCG vaccine is used as a vehicle to deliver distinctive proteins that originate from the SARS-CoV-2 virus surface. The goal is for the human immune system to develop a memory of SARS-CoV-2 and develop immunity.

There is currently global interest in the BCG vaccine, which is being investigated in ongoing clinical trials as a possible intervention to protect vulnerable people during the COVID-19 pandemic.

This is because of suggestions the BCG vaccine has other beneficial effects on the immune system that could protect against other infections. A 2019 observational study reported the vaccine is related to fewer deaths from certain infections other than from TB in low-income countries.

However, current COVID-19 related studies only investigate the protective effects of the BCG vaccine by itself.

Dr Claudio Counoupas, research scientist at the Centenary Institute and co-lead on the project, said: “Combining a part of the SARS-CoV-2 virus with BCG is key to this new vaccine.”

“This provides a specific ‘memory’ immune response against the virus that could provide long-term protection against disease. Our on-going studies will determine how long the  immune response lasts after vaccination in animal models. This is important information for future human testing of our vaccine.”

Professor Triccas said animal studies were necessary to ensure the vaccine is inducing the right type of immune response.

“These are critical before moving any candidate vaccine into human clinical trials.”

Themes

  • Inflammation

    Inflammation

Media enquires

For all media and interview enquiries, please contact Tony Crawshaw, Media and Communications Manager

Phone number Phone Number 0402 770 403

Email Email t.crawshaw@centenary.org.au

Recent Stories

  • Metastatic cancer research boosted

    Dr Dannel Yeo from the Centenary Institute and Clinical Associate Professor Kate Mahon from Chris O’Brien Lifehouse, have been awarded an inaugural Sydney Cancer Partners Translational Fellowship.
    News Type: Research News
    Date 03 Mar 2023
  • The Year That Made Me: Professor John Rasko

    Professor John Rasko AO, Head of the Gene and Stem Cell Therapy Program at the Centenary Institute has featured on the popular Radio National show Sunday Extra in the segment called ‘The Year That Made Me’.
    News Type: Media coverage
    Date 21 Feb 2023
  • Top abstract prize for gene therapy research

    Professor John Rasko AO and team have received the top scoring abstract award at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders in Manchester.
    News Type: Research News
    Date 15 Feb 2023
  • Event celebrates ‘The Good Gut Anti-Inflammatory Diet’

    The Centenary Institute has celebrated the publication of a new book, 'The Good Gut Anti-Inflammatory Diet’ at a special event, held at the Dymocks Bookstore, Sydney.
    News Type: Community
    Date 13 Feb 2023

Subscribe to receive news on
research updates and free events

Newsletter

The Centenary Institute is a world-leading independent Medical Research Institute.

We acknowledge the Gadigal of the Eora Nation, the traditional custodians of the Country on which the Centenary Institute stands.

About

  • About
  • Governance
  • Corporate information

Research

  • Programs
  • Our researchers
  • News
  • Media hub

Careers & studies

  • Career opportunities
  • Life at Centenary

Links

  • Contact
  • Privacy statement

Contact us

Building 93, Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050 Australia
Telephone +61 2 9565 6100
Fax +61 2 9565 6101

Centenary Institute ABN 22 654 201 090 (DGR 1) • Centenary Institute Medical Research Foundation ABN 85 778 244 012 (DGR 2)
© 2017 Centenary Institute of Cancer Medicine and Cell Biology.

  • Linkedin
  • Facebook
  • Twitter
  • Youtube
  • Instagram